CI.RatioF: 1-2*alpha Fieller CI given point estimate, CV (, CVb) and n

View source: R/BE_CI.R

CI.RatioFR Documentation

1–2*alpha Fieller CI given point estimate, CV (, CVb) and n


Utility function to calculate the 1–2α Fieller confidence interval given the point estimate, CV (, CVb), and n for the parallel group and 2×2 crossover.


CI.RatioF(alpha = 0.025, pe, CV, CVb, n, design = c("2x2", "parallel"))



Type I error probability, aka significance level.
Defaults here to 0.025 because this function is intended for studies with clinical endpoints.


Point estimate of T/R ratio.


Coefficient of variation as ratio (not percent). In case of design="parallel" this is the CV of the total variability, in case of design="2x2" the intra-subject CV.


CV of the between-subject variability. Only necessary for design="2x2".


Total number of subjects if a scalar is given.
Number of subjects in (sequence) groups if given as vector.


A character string describing the study design.
design="parallel" or design="2x2" allowed for a parallel two-group design or a classical TR|RT crossover design.


The CV(within) and CVb(etween) in case of design="2x2" are obtainedvia an appropriate ANOVA from the error term and from the difference (MS(subject within sequence)-MS(error))/2.


Returns the 1–2α confidence interval.


The function assumes an evaluation using un-transformed data.
The function assumes equal variances in case of design="parallel".
The formula implemented covers balanced and unbalanced designs.

Note that when the mean of the denominator of the ratio is close to zero, confidence intervals might be degenerated and are returned as NA. In such a case a warning is issued.

Whether the function vectorizes properly is not thoroughly tested.

This function is intended for studies with clinical endpoints. In such studies the 95% confidence intervals are usually used for equivalence testing. Therefore, alpha defaults here to 0.025 (see EMA 2000).


D. Labes


Locke CS. An exact confidence interval from untransformed data for the ratio of two formulation means. J Pharmacokin Biopharm. 1984;12(6):649–55. doi: 10.1007/BF01059558

Hauschke D, Steinijans VW, Pigeot I. Bioequivalence Studies in Drug Development. Chichester: John Wiley; 2007. Chapter 10. doi: 10.1002/9780470094778.fmatter

European Medicines Agency, Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. London, 27 July 2000. CPMP/EWP/482/99

See Also

CI.BE, power.RatioF


# 95% Fieller CI for the 2x2 crossover
CI.RatioF(pe = 0.95, CV = 0.3, CVb = 0.6, n = 32)

PowerTOST documentation built on March 18, 2022, 5:47 p.m.